Leading food retailers in the United Kingdom are beginning to register tangible effects on shopping habits as a growing number of consumers adopt appetite-suppressing medications, particularly glucagon-like peptide-1 (GLP-1) drugs.

Industry data shows that while overall grocery sales in value terms rose modestly in late 2025, the volume of food purchased fell slightly, a trend executives attribute in part to the influence of medical weight-loss aids which reduce hunger and alter dietary preferences.

Around five per cent of the UK’s adult population is now reported to use these drugs, and the impact is becoming visible at the supermarket checkout.

Retailers such as Sainsbury’s and Tesco have acknowledged that consumers appear to be shifting their baskets toward fresher, nutrient-dense foods, with strong performances from fresh produce, high-protein items and low- or no-alcohol beverages.

Sainsbury’s chief executive highlighted an increased selection of fibre-rich and healthier options among customers who are taking these drugs, while Tesco noted that fresh food outperformed other categories during the Christmas period, reflecting evolving demand patterns.

Executives emphasise that these shifts align with longer-term health trends as well as the specific effects of appetite suppression.

Fast-food and bakery chain Greggs has also adapted its product range in response, offering smaller portions and emphasising protein and fibre content amid indications that customers on GLP-1 therapies are choosing lighter meals and snacks.

Marks & Spencer has introduced a line of “nutrient-dense” meals tailored to consumers using weight-loss injections, reflecting broader industry efforts to cater to changing tastes and reduced appetite.

Analysts say these emerging consumer behaviours have the potential to reshape food retail, reducing demand for highly processed, calorie-dense products while increasing interest in healthy, portion-controlled options.